Favezelimab

Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902) . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) [1][2].

Product Specifications

CAS Number

[2231068-83-8]

Product Name Alternative

MK-4280; Mavezelimab

UNSPSC

12352203

Target

LAG-3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/favezelimab.html

Purity

97.79

Solubility

H2O

Smiles

[Favezelimab]

Molecular Weight

(145.98 kDa)

References & Citations

[1]Carmen Belli, et al. Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies. Cancers (Basel) . 2022 Sep 1;14 (17) :4278.|[2]Gareth P. Gregory, et al. Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: A Phase I/II study. Cancer Res (2019) 79 (13_Supplement) : CT106.